Nithya Balakrishnan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nithya Balakrishnan has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Jebiti Haribabu
Facultad de Medicina, Universidad de Atacama, Los Carreras 1579, 1532502 Copiapo, Chile
3 shared publications - Ramasamy Karvembu
National Institute of Technology
3 shared publications - Srividya Swaminathan
Chennai Institute of Technology (CIT) Chennai Tamil Nadu India
3 shared publications - Cesar Echeverria
ATACAMA OMICS, Laboratory of Molecular Biology and Genomics, Faculty of Medicine, University of Atacama, Copiapo, Chile
1 shared publication - Dasararaju Gayathri
Centre of Advanced Study in Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai 600025, India
1 shared publication - Dharmasivam Mahendiran
Centre for Cancer Cell Biology and Drug Discovery, Institute for Biomedicine and Glycomics, Griffith University, Southport, Queensland, Australia
1 shared publication
Latest Publications
- 6 June 2022
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (7)
Impact of denticity of chromone/chromene thiosemicarbazones in the ruthenium(II)‐DMSO complexes on their cytotoxicity against breast cancer cells
Denticity plays a prominent role in the cytotoxicity of metal complexes. The impact of ligand denticity of chromone/chromene thiosemicarbazones (TSCs) in the Ru(II)‐DMSO complexes on the cytotoxicity of cancer cells was evaluated. Ru(II)‐DMSO complex containing tridentate chromone TSC (D1) exhibited better in vitro anticancer activity than the one with bidentate chromene TSC (D2). Using the optimized structures of the complexes, the reason behind the same was attributed to the thermodynamically stable nature of the tridentate system. Hydrolysis study of the complexes showed the kinetically labile nature of the chloride ligand in the tridentate species with respect to the bidentate counterpart. The selective cytotoxicity of complex D1 against breast cancer cells and its less toxicity against normal cells demonstrated the effective anticancer potential of the complex. Further, the binding efficacy of the complexes against DNA and BSA, along with imaging and flow cytometry experiments, warranted the effective cell death induced by the complexes against breast cancer cells via apoptosis.
- 6 June 2022
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (7)
Impact of denticity of chromone/chromene thiosemicarbazones in the ruthenium(II)‐DMSO complexes on their cytotoxicity against breast cancer cells
Denticity plays a prominent role in the cytotoxicity of metal complexes. The impact of ligand denticity of chromone/chromene thiosemicarbazones (TSCs) in the Ru(II)‐DMSO complexes on the cytotoxicity of cancer cells was evaluated. Ru(II)‐DMSO complex containing tridentate chromone TSC (D1) exhibited better in vitro anticancer activity than the one with bidentate chromene TSC (D2). Using the optimized structures of the complexes, the reason behind the same was attributed to the thermodynamically stable nature of the tridentate system. Hydrolysis study of the complexes showed the kinetically labile nature of the chloride ligand in the tridentate species with respect to the bidentate counterpart. The selective cytotoxicity of complex D1 against breast cancer cells and its less toxicity against normal cells demonstrated the effective anticancer potential of the complex. Further, the binding efficacy of the complexes against DNA and BSA, along with imaging and flow cytometry experiments, warranted the effective cell death induced by the complexes against breast cancer cells via apoptosis.
- 15 October 2021
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 50 (44) , 16311-16325
Impact of aliphatic acyl and aromatic thioamide substituents on the anticancer activity of Ru(ii)-p-cymene complexes with acylthiourea ligands—in vitro and in vivo studies
Six acylthiourea-based Ru(ii)-p-cymene complexes (P1–P6) were designed to explore the structure–activity relationship of the complexes under the influence of aliphatic chain length and aromatic conjugation on the C- and N-terminals, respectively.
- 15 October 2021
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 50 (44) , 16311-16325
Impact of aliphatic acyl and aromatic thioamide substituents on the anticancer activity of Ru(ii)-p-cymene complexes with acylthiourea ligands—in vitro and in vivo studies
Six acylthiourea-based Ru(ii)-p-cymene complexes (P1–P6) were designed to explore the structure–activity relationship of the complexes under the influence of aliphatic chain length and aromatic conjugation on the C- and N-terminals, respectively.
- 6 January 2021
- Published by Wiley in Chemistry – A European Journal
- Vol. 27 (26) , 7418-7433
Tunable Anticancer Activity of Furoylthiourea‐Based RuII–Arene Complexes and Their Mechanism of Action
Fourteen new RuII–arene (p‐cymene/benzene) complexes (C1–C14) have been synthesized by varying the N‐terminal substituent in the furoylthiourea ligand and satisfactorily characterized by using analytical and spectroscopic techniques. Electrostatic potential maps predicted that the electronic effect of the substituents was mostly localized, with some influence seen on the labile chloride ligands. The structure–activity relationships of the Ru–p‐cymene and Ru–benzene complexes showed opposite trends. All the complexes were found to be highly toxic towards IMR‐32 cancer cells, with C5 (Ru–p‐cymene complex containing C6H2(CH3)3 as N‐terminal substituent) and C13 (Ru–benzene complex containing C6H4(CF3) as N‐terminal substituent) showing the highest activity among each set of complexes, and hence they were chosen for further study. These complexes showed different behavior in aqueous solutions, and were also found to catalytically oxidize glutathione. They also promoted cell death by apoptosis and cell cycle arrest. Furthermore, the complexes showed good binding ability with the receptors Pim‐1 kinase and vascular endothelial growth factor receptor 2, commonly overexpressed in cancer cells.
- 6 January 2021
- Published by Wiley in Chemistry – A European Journal
- Vol. 27 (26) , 7418-7433
Tunable Anticancer Activity of Furoylthiourea‐Based RuII–Arene Complexes and Their Mechanism of Action
Fourteen new RuII–arene (p‐cymene/benzene) complexes (C1–C14) have been synthesized by varying the N‐terminal substituent in the furoylthiourea ligand and satisfactorily characterized by using analytical and spectroscopic techniques. Electrostatic potential maps predicted that the electronic effect of the substituents was mostly localized, with some influence seen on the labile chloride ligands. The structure–activity relationships of the Ru–p‐cymene and Ru–benzene complexes showed opposite trends. All the complexes were found to be highly toxic towards IMR‐32 cancer cells, with C5 (Ru–p‐cymene complex containing C6H2(CH3)3 as N‐terminal substituent) and C13 (Ru–benzene complex containing C6H4(CF3) as N‐terminal substituent) showing the highest activity among each set of complexes, and hence they were chosen for further study. These complexes showed different behavior in aqueous solutions, and were also found to catalytically oxidize glutathione. They also promoted cell death by apoptosis and cell cycle arrest. Furthermore, the complexes showed good binding ability with the receptors Pim‐1 kinase and vascular endothelial growth factor receptor 2, commonly overexpressed in cancer cells.